Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Other solid neoplasm 1

Conditions

Recurrence 1Mesothelioma, Malignant 1Lymphoma, Large B-Cell, Diffuse 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Cisplatin 6Platinum 5Pemetrexed 51,2-diaminocyclohexaneplatinum II citrate 5pembrolizumab 4atezolizumab 2Radiotherapy 2Radiation 2Nivolumab 2Ipilimumab 2Gemcitabine 2Cyclophosphamide 2Carboplatin 2tremelimumab 1methoxyamine 1fludarabine 1decitabine and cedazuridine drug combination 1cediranib 1anetumab ravtansine 1aldesleukin 1Trioxsalen 1Tissue Banks 1Radiotherapy, Intensity-Modulated 1Proton Therapy 1Phototherapy 1Photochemotherapy 1Pharmacogenomic Testing 1Pharmaceutical Preparations 1Interleukin-2 1Influenza Vaccines 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Mesothelioma, Malignant × Combined Modality Therapy × 90 days × Clear all
NCT06251310 2026-05-08

SW-682 in Advanced Solid Tumors

Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany

Phase 1 Recruiting
186 enrolled
Other solid neoplasmThoracic

Mesothelioma, Malignant

Data powered by HemOnc (CC BY 4.0) Colophon âš¡